Rosaceiform dermatitis associated with topical tacrolimus treatment.
We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis. Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis. Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.
Fujiwara
Shoko
S
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Okubo
Yukari
Y
Irisawa
Ryokichi
R
Tsuboi
Ryoji
R
D000287:Administration, Topical; D000368:Aged; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012393:Rosacea / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000473:pathology; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*; D013684:Telangiectasis / Q000473:pathology
D007166:Immunosuppressive Agents; D016559:Tacrolimus